FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application        CTx-1301 Could Benefit >60% of ADHD Patients Currently ...

Related Keywords

United States ,Kansas City ,Kansas ,American ,Shanej Schaffer ,Matt Kreps ,Thomas Dalton ,Ann Childress ,Drug Administration ,Behavior Medicine Inc ,Platform Technology ,Securities Exchange ,Darrow Associates ,Psych Congress First Annual Poster ,Exchange Commission ,Psych Congress ,Nasdaq ,Cingulate Inc ,American Professional Society ,Date Sufficient ,New Drug Application ,Currently Using Immediate Release Booster ,Precision Timed Release ,Attention Deficit Hyperactivity Disorder ,Cingulate Chairman ,Behavior Medicine ,Professional Society ,Related Disorders ,First Annual Poster ,Hyperactivity Disorder ,Erosion Barrier Layer ,Looking Statements ,Securities Act ,Securities Exchange Act ,Annual Report ,Public Relations ,